Seaport Reports Positive GlyphAllo Driving Trial Results In Healthy Volunteers

Seaport Therapeutics (SPTX) reported positive Phase 1 trial results for GlyphAllo, showing no next-morning driving impairment at 375 mg and 250 mg doses. The trial met primary and key secondary endpoints. GlyphAllo is being developed for major depressive disorder (MDD) and is currently in a Phase 2b trial, with topline data expected in 2027. The company plans to submit these results to the FDA.

Seaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 d

PureTech’s founded entity Seaport Therapeutics reported positive Phase 1 multiple-ascending dose data for GlyphAgo (SPT-320) in healthy volunteers. Seaport said seven-day repeat dosing showed favorable safety/tolerability and PK consistent with prior single-dose results, with no liver-related adverse events and dose-dependent agomelatine exposure. Seaport plans Phase 2a in H2 2026 (topline early 2028) and Phase 2b in H1 2027 (topline by end-2028).

Seaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress New data from Phase 1 trial of GlyphAgo TM build upon previously reported topline data and further demons

Ionis Pharmaceuticals (IONS) shares have fallen over 40% this year, despite analysts maintaining an average price target of $83.82. The company has six approved therapies, primarily for rare diseases, and is developing eight more in late-stage trials. Ionis reported a 40.7% revenue decline and a net loss in Q2, but analysts highlight its antisense oligonucleotide technology and potential for future growth.

GLOBALFOUNDRIES (GFS) secured $375M in CHIPS R&D funding and $300M for silicon photonics. Its stock rose 4.32% recently, but is down 46.67% over 90 days. Analysts value it at $76, 37% above its last close of $47.82, citing its global manufacturing and government incentives. However, risks include weak smartphone demand and high capital spending.